Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.64 |
| ▸ | TNF | P01375 | 5/20 | 0.64 |
| ▸ | IL1B | P01584 | 4/20 | 0.64 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.51 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25726981 | 1.00 | CRBN (0.65) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25653782 | 1.00 | CRBN (0.65) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19611984 | 0.94 | CRBN (0.56) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21107124 | 0.89 | CRBN (0.70) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL17299698 | 0.89 | CRBN (0.70) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21107638 | 0.89 | CRBN (0.70) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24764835 | 0.87 | CRBN (0.67) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL23594393 | 0.87 | CRBN (0.67) | CRBNIKZF3TNFIL1BIKZF1 | |
| Hydrochloric Acid SCHEMBL27777888 | 0.86 | CRBN (0.68) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30619652 | 0.84 | CRBN (0.56) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | SONATA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | GRK2, GRK3, GRK1 | CRBN 675/4885IKZF3 2514/4885TNF 4799/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885IKZF3 135/4885TNF 172/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CRBN 302/4885IKZF3 931/4885TNF 4483/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | CRBN 183/4885IKZF3 1423/4885TNF 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.